Liquid biopsy assessment during chemotherapy for CRCs has proved the acquisition of mutations in various oncogenes, including RAS or BRAF genes, tumor suppressor genes, or genes involved in the deoxyribonucleic acid (DNA) repair process, and the development of chemotherapy resistance [2–4]; the acquisition of these mutations has been shown to occur even in chemosensitive tumors to some degree [5]. This evidence concerns the gene BRAF and neoplasm.